Table 2.
Treatment planning goals for [18F]fluciclovine PET-MRI directed nodal dose escalation
| Structure | Dosimetric parameter | Per protocol | Variation acceptable |
|---|---|---|---|
| PTVP+SV | V70 Gy[%] | ≥95% | ≥90% |
| Maximum dose | <75 Gy | <77 Gy | |
| PTVLN BOOST | V60.2 Gy[%] | ≥90% | -∗ |
| Maximum dose | <66 Gy | <68 Gy | |
| PTVeLN | V50.4 Gy[%] | ≥95% | ≥90% |
| Rectum | V70 Gy[cc] | <3 cm3 | <5 cm3 |
| V60 Gy[%] | <10% | <15% | |
| V50 Gy[%] | <25% | <40% | |
| Small bowel | Maximum dose | <54 Gy | <58 Gy |
| V54 Gy[cc] | 0 cm3 | <20 cm3 | |
| V45 Gy[cc] | <120 cm3 | Not specified | |
| Bladder | V60 Gy[%] | <20% | <25% |
| V40 Gy[%] | <50% | <65% | |
| Femoral heads | V50 Gy[%] | <5% | <10% |
Abbreviations: CTV = clinical target volume; LN = lymph node; MRI = magnetic resonance imaging; P + SV = prostate and seminal vesicles; PET = positron emission tomography; PTV = planning target volume.
∗
No minimum acceptable coverage of PTVLN BOOST is specified due to potential overlap between the target volume and bowel structures is may occur. In such instances effort should be made to ensure CTVLNBOOST V60.2 Gy[%] ≥90%.